U.K. Launches It's Strategic Vision for Global Leadership and Ethical Innovation Using AI
At Lanton Law and our sister company Lanton Strategies International, we are watching multiple developments worldwide on the usage of AI. Most recently, our attention has focused on the events in the United Kingdom.
At Lanton Law and our sister company Lanton Strategies International, we are watching multiple developments worldwide on the usage of AI. Most recently, our attention has focused on the events in the United Kingdom.
With the UK Prime Minister Sir Keir Starmer’s speech on the U.K.’s AI strategy, the Prime Minister has put forward a bold vision to position the United Kingdom as a global leader in artificial intelligence. With a focus on fostering innovation, ethical leadership, and practical application, the government is leveraging AI to drive economic growth, modernize public services, and secure its position in the competitive global AI landscape.
The AI Opportunities Action Plan serves as the cornerstone of this vision, laying out a comprehensive framework for integrating AI into the UK economy. The government has attracted significant private-sector investment, including a commitment of £14 billion from leading tech firms, and aims to create over 13,000 jobs. AI Growth Zones are a pivotal part of the strategy, designed to streamline planning for research and development hubs that will foster collaboration across academia, industry, and government.
Modernizing public services is another critical objective. AI tools like Parlex are already being developed to streamline decision-making processes within the public sector. By reducing administrative burdens, civil servants can focus on improving service delivery for citizens.
On the global stage, the UK is carving a niche in ethical AI leadership, hosting the inaugural AI Safety Summit in November 2023. The resulting Bletchley Declaration emphasizes international cooperation on the safe development and use of AI, aligning with the UK’s commitment to balancing innovation with responsibility.
Despite these efforts, challenges remain. Competing with AI superpowers like the US and China requires pragmatic goal-setting and leveraging the UK’s strengths in education and professional services. By focusing on fintech, ethical AI, and sustainable innovation, the UK can strategically navigate the competitive AI environment.
In summary, Prime Minister Starmer’s AI stance reflects a forward-thinking approach that combines ambition with practicality, ensuring the UK remains a key player in shaping the future of AI.
For additional questions on this and any other policy or regulatory matters where AI is concerned, contact us for details.
FDA Releases Artificial Intelligence/Machine Learning Action Plan
Earlier this month, the FDA released its first Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD) Action Plan.
As part of its breakthrough, the FDA pointed out some interesting aspects of its new policy area.
Earlier this month, the FDA released its first Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD) Action Plan.
As part of its breakthrough, the FDA pointed out some interesting aspects of its new policy area.
“Consistent with FDA’s longstanding commitment to develop and apply innovative approaches to the regulation of medical device software and other digital health technologies, in April of 2019, FDA published the “Proposed Regulatory Framework for Modifications to Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD) - Discussion Paper and Request for Feedback.” This paper described the FDA’s foundation for a potential approach to premarket review for artificial intelligence and machine learning-driven software modifications. The ideas delineated in the discussion paper leveraged practices from our current premarket programs and relied on the International Medical Device Regulators Forum’s risk categorization principles, the FDA’s benefit-risk framework, risk management principles described in the software modifications guidance, and the organization-based total product lifecycle approach also envisioned in the Digital Health Software Precertification (Pre-Cert) Pilot Program.
As part of this proposed framework, FDA described a “Predetermined Change Control Plan” in premarket submissions. This plan would include the types of anticipated modifications—referred to as the “SaMD Pre-Specifications”—and the associated methodology being used to implement those changes in a controlled manner that manages risks to patients —referred to as the “Algorithm Change Protocol.” In this approach, FDA expressed an expectation for transparency and real-world performance monitoring by manufacturers that could enable FDA and manufacturers to evaluate and monitor a software product from its premarket development through postmarket performance. This framework would enable FDA to provide a reasonable assurance of safety and effectiveness while embracing the iterative improvement power of artificial intelligence and machine learning-based software as a medical device.”
Lanton Law is an innovative firm at the center of tomorrow’s legal, policy and market trends. We continue to monitor the developments of emerging sectors such as AI and give counsel to stakeholders accordingly. Contact Lanton Law to discuss your lobbying and legal strategies.
FDA Announces the Launch of its Digital Health Center of Excellence
With all the attention on the 2020 elections, what may have been lost in the fray was the announcement that the FDA created the Digital Health Center of Excellence, within the Center for Devices and Radiological Health (CDRH). According to the FDA’s release, the new Center is dedicated “to the advancement of digital health technology, including mobile health devices, Software as a Medical Device (SaMD), wearables when used as a medical device, and technologies used to study medical products.”
With all the attention on the 2020 elections, what may have been lost in the fray was the announcement that the FDA created the Digital Health Center of Excellence, within the Center for Devices and Radiological Health (CDRH). According to the FDA’s release, the new Center is dedicated “to the advancement of digital health technology, including mobile health devices, Software as a Medical Device (SaMD), wearables when used as a medical device, and technologies used to study medical products.”
So what is the mission of the Digital Health Center of Excellence? According to the FDA:
“The Digital Health Center of Excellence is primarily focused on helping both internal and external stakeholders achieve their goals of getting high quality digital health technologies to patients by providing technological advice, coordinating and supporting work being done across the FDA, advancing best practices, and reimagining digital health device oversight. Along those lines, the Digital Health Center of Excellence is creating a network of digital health experts and engaging in Collaborative Communities to share knowledge and experience concerning digital health issues and priorities with FDA staff. An integral part of the launch includes the activities that will be provided to complement advances in digital health technology – such as launching strategic initiatives that advance digital health technologies, facilitating synergies in regulatory science research in digital health, and facilitating and building strategic partnerships.”
As COVID 19 has forced our society to become more mobile and technologically dependent, the trends of big data, AI, machine learning and mobile health to name a few are here to stay.
Lanton Law is an innovative firm that sees itself at the center of tomorrow’s legal, policy and market trends. We continue to monitor the developments of emerging sectors and give counsel to stakeholders in highly regulated industries. If you are a stakeholder examining your options for this year and need advice, contactLanton Law to discuss yourlobbying andlegal strategies.